Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX)
may provide an advantage over other oral agents approved for alcohol and opioid dependence
treatment. The objective of this study was to evaluate cost and utilization outcomes between
XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence.
Published studies were...